Condition Directory

Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Cancer. Browse Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced July 24, 2026 Report an issue

ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

Shown on this page

Current sort

How Cancer studies are organized in the registry

“Cancer” is the broadest term in the registry, and most oncology records list a specific cancer type rather than the umbrella word. If you are researching a particular diagnosis, the dedicated pages for that cancer type usually give a cleaner result set. Tumor-agnostic and basket studies are the exception — they often appear under generic terms instead of a single organ site.

Terms that often appear in related listings

solid tumor advanced solid tumors metastatic basket trial

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 13–24 of 12 matching trials for Cancer.

Live ClinicalTrials.gov results.

Active filters: "solid tumor" Clear condition filters

Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer
Interventions: BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 10
States / cities: Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 7 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: sigvotatug vedotin, docetaxel; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 130
States / cities: Anchorage, Alaska • Fullerton, California • Los Alamitos, California + 91 more

Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions: Bevacizumab, Cetuximab, Computed Tomography, Floxuridine, Fluorouracil, Implantation, Intrahepatic Infusion Procedure, Irinotecan, Leucovorin, Oxaliplatin, Panitumumab, Single Photon Emission Computed Tomography; Biological · Procedure · Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 60
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 47 more

Conditions: Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
Interventions: Torvutatug samrotecan, Saruparib, Bevacizumab, Carboplatin, Palacaparib, Pembrolizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 13
States / cities: Duarte, California • Irvine, California • La Jolla, California + 9 more

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer, Colorectal Cancer, Gastric Cancer, dMMR Cancer
Interventions: MOMA-341, Irinotecan, Immunotherapy; Drug
Lead sponsor: MOMA Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Phoenix, Arizona • San Diego, California • Tampa, Florida + 6 more

Conditions: Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Selumetinib Sulfate; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 293
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 230 more

Conditions: Very Rare Tumors, Very Rare Cancers, Other Solid Tumors, Solid Tumor, Pediatric Rare Tumors
Interventions: Natural history study of individuals with very rare tumors; Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Month to 120 Years
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
Interventions: IV ICT01; Biological
Lead sponsor: ImCheck Therapeutics, an Ipsen company; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Gilbert, Arizona • Duarte, California • New Haven, Connecticut + 5 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: BI 770371, Pembrolizumab, Cetuximab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Louisville, Kentucky • Minneapolis, Minnesota • Columbus, Ohio

Conditions: Solid Tumors, Sarcomas
Interventions: ZL-6201; Drug
Lead sponsor: Zai Lab (Shanghai) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Los Angeles, California • New Haven, Connecticut • Sarasota, Florida + 3 more

Conditions: Lung Cancer, Non-squamous, Non-small Cell
Interventions: zongertinib, pembrolizumab, cisplatin, carboplatin, pemetrexed; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 22
States / cities: Huntsville, Alabama • Bullhead City, Arizona • Beverly Hills, California + 19 more

Conditions: Ovarian Cancer
Interventions: misetionamide (also known as GP-2250); Drug
Lead sponsor: Persevere Therapeutics Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Fairway, Kansas • Boston, Massachusetts + 1 more

About this Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Cancer clinical trials

How Cancer studies are organized in the registry

Filter and sort this condition

Live official records

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

First-in-Human Study of ICT01 in Patients With Advanced Cancer

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine

About this Cancer clinical trials directory page